Computer Software Assurance (CSA) is FDA's updated framework for assuring the quality and fitness-for-purpose of software used in GxP-regulated environments. Published as final guidance in September 2022, CSA replaces the prescriptive documentation-heavy approach of legacy CSV with a critical thinking, risk-based methodology. The focus shifts from producing volumes of documentation to demonstrating genuine understanding of how software supports patient safety and product quality.
CSV (Computer System Validation) follows a prescriptive lifecycle model — typically IQ, OQ, PQ — with extensive pre-defined documentation regardless of actual risk. CSA is FDA's risk-proportionate replacement: it applies critical thinking to determine how much testing and documentation each function genuinely warrants. Low-risk configurations may need minimal documentation; high-risk, patient-impacting functions require rigorous evidence. CSA reduces unnecessary compliance burden while maintaining — and in many respects improving — the quality of assurance.
The September 2022 final guidance formalized CSA as the FDA's official position on computer software validation in GxP environments. Key changes include: explicit endorsement of risk-based, critical thinking documentation over scripted test overproduction; recognition that vendor testing evidence can satisfy validation requirements where appropriate; acknowledgment that unscripted testing (exploratory, ad hoc) is a legitimate validation approach; and a clear move away from the 1987 General Principles of Software Validation as the primary reference.
CSA is not yet a formal regulatory requirement, but it represents the FDA's strongly preferred direction and the modern interpretation of existing GxP obligations. Companies continuing to use legacy CSV approaches are not immediately non-compliant, but they face increasing documentation overhead and growing misalignment with inspector expectations. Adopting CSA now reduces audit risk, improves efficiency, and future-proofs the validation function as FDA guidance continues to evolve.
In CSA, critical thinking means applying expert judgment to determine what assurance activities genuinely reduce risk to product quality and patient safety — rather than following a fixed documentation template. It involves asking: What could go wrong with this function? What is the realistic consequence? What level of evidence is proportionate to that risk? The answer drives testing depth, documentation detail, and the decision to leverage vendor evidence or perform independent testing.
Yes. One of CSA's most significant departures from legacy CSV is its explicit endorsement of vendor-supplied test evidence. Where a software supplier can provide credible, well-documented test data — SOC 2 reports, IQOQ protocols, test logs, SaaS validation packages — regulated companies can leverage this evidence instead of repeating the same tests. The company must still assess the vendor's quality system and the relevance of the evidence to their specific use case, but CSA removes the presumption that everything must be re-tested from scratch.
Unscripted testing under CSA refers to exploratory, ad hoc, or session-based testing where the tester uses judgment rather than executing a pre-written script. It is appropriate for lower-risk functions, configuration verification, and usability assessment where a rigid scripted protocol would add effort without adding meaningful assurance. The critical requirement is documentation of the testing rationale, approach, and outcome — evidence that informed professional judgment was applied, not just that tests were run.
CSA and GAMP 5 Second Edition (2022) are complementary frameworks aligned on the same core principle: risk-based, proportionate validation. GAMP 5 Second Edition explicitly incorporated CSA thinking, including the use of vendor evidence, critical thinking, and streamlined documentation. Organizations implementing GAMP 5 Second Edition are, in effect, implementing a CSA-compatible approach. FDA's CSA guidance can be seen as the regulatory signal; GAMP 5 Second Edition as the practical implementation framework.
CSA does not prescribe a specific document set. Instead, it requires sufficient documented evidence to demonstrate that critical thinking was applied, risks were identified and addressed, and the software is fit for its intended GxP use. At minimum, this typically includes: a documented critical thinking rationale, a risk assessment, testing evidence (scripted, unscripted, or vendor-supplied), and a summary or validation report. The principle is proportionality — the documentation should match the actual risk profile of the system and function.
No. CSA changes how you approach validation planning and documentation, but it does not modify 21 CFR Part 11 requirements for electronic records or electronic signatures. Systems that create, modify, or transmit GxP records electronically must still maintain secure, computer-generated audit trails, enforce access controls, and support electronic signature requirements. CSA changes the validation approach; 21 CFR Part 11 requirements apply independently based on system function.
CSA itself does not reference GAMP software categories directly, but the GAMP 5 Second Edition framework — which is fully CSA-aligned — continues to use categories as one tool for establishing baseline risk levels. Category 3 (non-configurable software), Category 4 (configurable software), and Category 5 (custom software) still provide useful starting points for risk assessment. Under CSA, category assignment informs but does not dictate the validation approach — critical thinking about actual function and patient impact is the determinant.
CSA is particularly well-suited to SaaS and cloud validation because it explicitly endorses vendor evidence — and SaaS suppliers typically maintain comprehensive test documentation, SOC 2 reports, and validation packages. For SaaS, the regulated company's CSA effort focuses on: assessing the vendor's quality system, mapping GxP-impacting functions, verifying configuration, and documenting critical thinking about residual risk. This is typically far less burdensome than a full IQ/OQ/PQ protocol and better reflects actual risk.
The FDA CSA guidance is a US regulatory document and does not formally apply in the EU. EU GMP Annex 11 remains the applicable framework for European operations. However, the principles of risk-based validation, vendor assessment, and proportionate documentation are consistent across both frameworks. Multinational organizations can develop harmonized CSA-aligned SOPs that satisfy both FDA and EU Annex 11 expectations — the core principles are compatible even though the specific guidance documents differ.
Transition from CSV to CSA is best approached systematically: first, update SOPs to incorporate critical thinking requirements and risk-based test planning; second, train validation teams on CSA principles and the distinction between documentation burden and genuine assurance; third, establish a vendor evidence management process for SaaS and commercial systems; and fourth, apply CSA principles to all new system validations immediately while applying risk-based revalidation triggers to existing systems. A full rip-and-replace of all existing CSV documentation is not required or advisable.
FDA inspectors assessing CSA-aligned validation look for evidence of genuine critical thinking — not just document completeness. They expect to see: documented rationale for why a given level of testing was applied, clear identification of high-risk functions and how they were addressed, and coherent traceability between requirements, risks, and test evidence. Thin documentation for genuinely complex high-risk systems, or excessive documentation that masks a lack of real understanding, are both inspector concerns under a CSA assessment mindset.
CSA does not mandate the IQ/OQ/PQ structure, but it does not prohibit it either. For systems where the three-phase approach remains the most logical and efficient way to organize testing and evidence, it continues to be appropriate. What CSA removes is the requirement to use this structure uniformly, regardless of system risk or complexity. A simple configurable SaaS tool may require no formal IQ/OQ/PQ; a complex custom manufacturing execution system may still benefit from the full structured qualification lifecycle.
CSA explicitly frames risk assessment around patient safety and product quality because these are the ultimate purposes of GxP regulation. Not all software failures have equal regulatory consequence: an error in a cosmetic UI field is fundamentally different from an error in a batch release calculation. By requiring critical thinking focused on patient impact, CSA ensures that validation effort is concentrated where it actually protects patients — rather than being spread uniformly across all system functions regardless of consequence.
CSA does not explicitly mandate an RTM, but traceability between user requirements, risk assessments, and test evidence is a logical outcome of the critical thinking approach. An RTM — or equivalent structured documentation — provides the clearest audit trail showing that each identified risk was addressed by proportionate testing. For complex systems with many GxP-impacting functions, an RTM remains best practice. For simpler configurations, a summary document mapping risks to testing outcomes may be sufficient.
Under CSA, change control requires the same critical thinking approach as initial validation. When a system changes, the relevant question is: does this change affect any function with GxP impact, and if so, what is the risk and what level of revalidation is proportionate? Not every update triggers a full requalification. Configuration changes, vendor patches, and feature additions must each be assessed for their specific impact on validated functions — with the assessment documented as part of the change control record.
No — CSA does not require retrospective revalidation of systems already validated under legacy CSV. A well-documented CSV validation record remains an acceptable compliance baseline. The CSA approach applies going forward: to new system implementations, major changes requiring revalidation, and periodic review activities. When legacy systems undergo significant change or revalidation, that is the natural point to transition to CSA-aligned documentation practices rather than reworking existing compliant records.